Cargando…
Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification?
BACKGROUND: Response to preoperative radiochemotherapy (RCT) in patients with locally advanced rectal cancer is very heterogeneous. Pathologic complete response (pCR) is accompanied by a favorable outcome. However, most patients show incomplete response. The aim of this investigation was to find ind...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864265/ https://www.ncbi.nlm.nih.gov/pubmed/20388220 http://dx.doi.org/10.1186/1477-7819-8-27 |
_version_ | 1782180766522802176 |
---|---|
author | Sprenger, Thilo Rothe, Hilka Jung, Klaus Christiansen, Hans Conradi, Lena C Ghadimi, B Michael Becker, Heinz Liersch, Torsten |
author_facet | Sprenger, Thilo Rothe, Hilka Jung, Klaus Christiansen, Hans Conradi, Lena C Ghadimi, B Michael Becker, Heinz Liersch, Torsten |
author_sort | Sprenger, Thilo |
collection | PubMed |
description | BACKGROUND: Response to preoperative radiochemotherapy (RCT) in patients with locally advanced rectal cancer is very heterogeneous. Pathologic complete response (pCR) is accompanied by a favorable outcome. However, most patients show incomplete response. The aim of this investigation was to find indications for risk stratification in the group of intermediate responders to RCT. METHODS: From a prospective database of 496 patients with rectal adenocarcinoma, 107 patients with stage II/III cancers and intermediate response to preoperative 5-FU based RCT (ypT2/3 and TRG 2/3), treated within the German Rectal Cancer Trials were studied. Surgical treatment comprised curative (R0) total mesorectal excision (TME) in all cases. In 95 patients available for statistical analyses, residual transmural infiltration of the mesorectal compartment, nodal involvement and histolologic tumor grading were investigated for their prognostic impact on disease-free (DFS) and overall survival (OS). RESULTS: Residual tumor transgression into the mesorectal compartment (ypT3) did not influence DFS and OS rates (p = 0.619, p = 0.602, respectively). Nodal involvement after preoperative RCT (ypN1/2) turned out to be a valid prognostic factor with decreased DFS and OS (p = 0.0463, p = 0.0236, respectively). Persistent tumor infiltration of the mesorectum (ypT3) and histologic tumor grading of residual tumor cell clusters were strongly correlated with lymph node metastases after neoadjuvant treatment (p < 0.001). CONCLUSIONS: Advanced transmural tumor invasion after RCT does not affect prognosis when curative (R0) resection is achievable. Residual nodal status is the most important predictor of individual outcome in intermediate responders to preoperative RCT. Furthermore, ypT stage and tumor grading turn out to be additional auxiliary factors. Future clinical trials for risk-adapted adjuvant therapy should be based on a synopsis of clinicopathologic parameters. |
format | Text |
id | pubmed-2864265 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28642652010-05-05 Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification? Sprenger, Thilo Rothe, Hilka Jung, Klaus Christiansen, Hans Conradi, Lena C Ghadimi, B Michael Becker, Heinz Liersch, Torsten World J Surg Oncol Research BACKGROUND: Response to preoperative radiochemotherapy (RCT) in patients with locally advanced rectal cancer is very heterogeneous. Pathologic complete response (pCR) is accompanied by a favorable outcome. However, most patients show incomplete response. The aim of this investigation was to find indications for risk stratification in the group of intermediate responders to RCT. METHODS: From a prospective database of 496 patients with rectal adenocarcinoma, 107 patients with stage II/III cancers and intermediate response to preoperative 5-FU based RCT (ypT2/3 and TRG 2/3), treated within the German Rectal Cancer Trials were studied. Surgical treatment comprised curative (R0) total mesorectal excision (TME) in all cases. In 95 patients available for statistical analyses, residual transmural infiltration of the mesorectal compartment, nodal involvement and histolologic tumor grading were investigated for their prognostic impact on disease-free (DFS) and overall survival (OS). RESULTS: Residual tumor transgression into the mesorectal compartment (ypT3) did not influence DFS and OS rates (p = 0.619, p = 0.602, respectively). Nodal involvement after preoperative RCT (ypN1/2) turned out to be a valid prognostic factor with decreased DFS and OS (p = 0.0463, p = 0.0236, respectively). Persistent tumor infiltration of the mesorectum (ypT3) and histologic tumor grading of residual tumor cell clusters were strongly correlated with lymph node metastases after neoadjuvant treatment (p < 0.001). CONCLUSIONS: Advanced transmural tumor invasion after RCT does not affect prognosis when curative (R0) resection is achievable. Residual nodal status is the most important predictor of individual outcome in intermediate responders to preoperative RCT. Furthermore, ypT stage and tumor grading turn out to be additional auxiliary factors. Future clinical trials for risk-adapted adjuvant therapy should be based on a synopsis of clinicopathologic parameters. BioMed Central 2010-04-13 /pmc/articles/PMC2864265/ /pubmed/20388220 http://dx.doi.org/10.1186/1477-7819-8-27 Text en Copyright ©2010 Sprenger et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Sprenger, Thilo Rothe, Hilka Jung, Klaus Christiansen, Hans Conradi, Lena C Ghadimi, B Michael Becker, Heinz Liersch, Torsten Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification? |
title | Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification? |
title_full | Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification? |
title_fullStr | Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification? |
title_full_unstemmed | Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification? |
title_short | Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification? |
title_sort | stage ii/iii rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification? |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864265/ https://www.ncbi.nlm.nih.gov/pubmed/20388220 http://dx.doi.org/10.1186/1477-7819-8-27 |
work_keys_str_mv | AT sprengerthilo stageiiiiirectalcancerwithintermediateresponsetopreoperativeradiochemotherapydowehaveindicationsforindividualriskstratification AT rothehilka stageiiiiirectalcancerwithintermediateresponsetopreoperativeradiochemotherapydowehaveindicationsforindividualriskstratification AT jungklaus stageiiiiirectalcancerwithintermediateresponsetopreoperativeradiochemotherapydowehaveindicationsforindividualriskstratification AT christiansenhans stageiiiiirectalcancerwithintermediateresponsetopreoperativeradiochemotherapydowehaveindicationsforindividualriskstratification AT conradilenac stageiiiiirectalcancerwithintermediateresponsetopreoperativeradiochemotherapydowehaveindicationsforindividualriskstratification AT ghadimibmichael stageiiiiirectalcancerwithintermediateresponsetopreoperativeradiochemotherapydowehaveindicationsforindividualriskstratification AT beckerheinz stageiiiiirectalcancerwithintermediateresponsetopreoperativeradiochemotherapydowehaveindicationsforindividualriskstratification AT lierschtorsten stageiiiiirectalcancerwithintermediateresponsetopreoperativeradiochemotherapydowehaveindicationsforindividualriskstratification |